Indeed, Xie et al. demonstrated that EVs produced by MM cells previously engineered to overexpress TNF-α can enhance the CD8+ T lymphocyte response in vivo preventing tumor growth after subcutaneously challenging mice immunized with MM-EVs. The gene discussed is CD8A; the disease is Miyoshi myopathy.